Myotonic muscular dystrophy type 1 is a chronic and slowly progressing genetic disease affecting many organs. It is the most…
Articles by Margarida Azevedo, MSc
Grace Century’s bio banking project, Provia Laboratories, LLC, a healthcare services company specializing in high-quality bio-banking (the collection,…
Akashi Therapeutics Inc. a biopharmaceutical company focused on developing treatments for patients with Duchenne muscular dystrophy (DMD) recently…
Non-profit organization Parent Project Muscular Dystrophy (PPMD) has nominated Duke Children’s Hospital & Health Center as a…
The U.S. Food and Drug Administration (FDA) granted orphan drug status to an investigational therapy being developed by MediciNova, Inc.
In a recent study published in Oncotarget, researchers found an inverse correlation between the level of muscle fibrosis,…
Managing muscular dystrophy (MD) is not an easy task, and it depends not only medical intervention, but also on…
Germany’s Federal Joint Committee (G-BA) published a positive Benefit Assessment for Translarna (ataluren), including an evaluation of the benefits of the drug in…
A chain of convenience stores has joined forces with the Muscular Dystrophy Association (MDA) to help improve the quality…
EspeRare, a company focused on uncovering the potential of existing molecules to address severe therapeutic unmet needs in rare diseases, recently…